

# Serkan Kuyumcu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2949573/publications.pdf>

Version: 2024-02-01

49  
papers

963  
citations

471509

17  
h-index

477307

29  
g-index

49  
all docs

49  
docs citations

49  
times ranked

1332  
citing authors

#	ARTICLE	IF	CITATIONS
1	Neuroendocrine Tumor Diagnosis and Management: <sup>68</sup> Ga-DOTATATE PET/CT. American Journal of Roentgenology, 2018, 211, 267-277.	2.2	133
2	Can Complementary <sup>68</sup> Ga-DOTATATE and <sup>18</sup> F-FDG PET/CT Establish the Missing Link Between Histopathology and Therapeutic Approach in Gastroenteropancreatic Neuroendocrine Tumors?. Journal of Nuclear Medicine, 2014, 55, 1811-1817.	5.0	82
3	Physiological and tumoral uptake of <sup>68</sup> Ga-DOTATATE: standardized uptake values and challenges in interpretation. Annals of Nuclear Medicine, 2013, 27, 538-545.	2.2	78
4	Increased FDG uptake in breast cancer is associated with prognostic factors. Annals of Nuclear Medicine, 2012, 26, 345-350.	2.2	57
5	The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels. Annals of Nuclear Medicine, 2012, 26, 551-558.	2.2	53
6	Safety of Fibroblast Activation Protein-Targeted Radionuclide Therapy by a Low-Dose Dosimetric Approach Using <sup>177</sup> Lu-FAPI04. Clinical Nuclear Medicine, 2021, 46, 641-646.	1.3	52
7	Comparison of <sup>68</sup> Ga-DOTATATE PET-CT, <sup>18</sup> F-FDG PET-CT and <sup>99m</sup> Tc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma. Nuclear Medicine Communications, 2015, 36, 242-250.	1.1	42
8	Relationships between serum PSA levels, Gleason scores and results of <sup>68</sup> Ga-PSMAPET/CT in patients with recurrent prostate cancer. Annals of Nuclear Medicine, 2017, 31, 709-717.	2.2	37
9	The Value of Somatostatin Receptor Imaging with In-111 Octreotide and/or Ga-68 DOTATATE in Localizing Ectopic ACTH Producing Tumors. Molecular Imaging and Radionuclide Therapy, 2013, 22, 49-55.	0.7	34
10	Evidence of Prostate-Specific Membrane Antigen Expression in Hepatocellular Carcinoma Using <sup>68</sup> Ga-PSMA PET/CT. Clinical Nuclear Medicine, 2019, 44, 702-706.	1.3	34
11	Survival analysis of <sup>90</sup> Y radiosynovectomy in the treatment of haemophilic synovitis of the knee: a 10-year retrospective review. Haemophilia, 2014, 20, e45-50.	2.1	28
12	Fibroblast-Activated Protein Inhibitor PET/CT: Cancer Diagnosis and Management. Frontiers in Oncology, 2021, 11, 758958.	2.8	25
13	Diagnostic spectrum of congenital hypothyroidism in Turkish children. Pediatrics International, 2009, 51, 464-468.	0.5	23
14	Somatostatin receptor scintigraphy with <sup>111</sup> In-octreotide in pulmonary carcinoid tumours correlated with pathological and <sup>18</sup> F-FDG PET/CT findings. Annals of Nuclear Medicine, 2012, 26, 689-697.	2.2	21
15	Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of <sup>18</sup> F-FDG-PET/CT according to $\hat{I}^m$ SUVmax, Deauville 5-point scale and IHP criteria. Annals of Nuclear Medicine, 2017, 31, 660-668.	2.2	21
16	Hepatic Adenomatosis May Mimic Metastatic Lesions of Liver With <sup>18</sup> F-FDG PET/CT. Clinical Nuclear Medicine, 2012, 37, 697-698.	1.3	20
17	Favorable Survival Time Provided with Radioembolization in Hepatocellular Carcinoma Patients with and Without Portal Vein Thrombosis. Cancer Biotherapy and Radiopharmaceuticals, 2015, 30, 132-138.	1.0	19
18	Prognostic significance of <sup>68</sup> Ga-Pentixafor PET/CT in multiple myeloma recurrence: a comparison to <sup>18</sup> F-FDG PET/CT and laboratory results. Annals of Nuclear Medicine, 2021, 35, 1147-1156.	2.2	18

#	ARTICLE	IF	CITATIONS
19	Fibroblast Activation Proteinâ€“Targeted PET Imaging of Metastatic Castration-Resistant Prostate Cancer Compared With 68Ga-PSMA and 18F-FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2022, 47, e54-e55.	1.3	18
20	Does bone scintigraphy still have a role in the era of 68Ga-PSMA PET/CT in prostate cancer?. <i>Annals of Nuclear Medicine</i> , 2020, 34, 476-485.	2.2	15
21	Correlation of 18F-FDG PET/CT with pathological features and survival in primary breast cancer. <i>Nuclear Medicine Communications</i> , 2017, 38, 694-700.	1.1	14
22	Radionuclide Therapy With 177Lu-PSMA in a Case of Metastatic Adenoid Cystic Carcinoma of the Parotid. <i>Clinical Nuclear Medicine</i> , 2019, 44, 764-766.	1.3	13
23	Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer?. <i>Annals of Nuclear Medicine</i> , 2021, 35, 680-690.	2.2	11
24	225Ac-Prostate-Specific Membrane Antigen Therapy for Castration-Resistant Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2021, 46, 943-951.	1.3	11
25	Imaging of Chemokine Receptor CXCR4 in Mycosis Fungoides Using 68Ga-Pentixafor PET/CT. <i>Clinical Nuclear Medicine</i> , 2018, 43, 606-608.	1.3	10
26	68Ga-DOTATATE PETâ€“CT imaging in carotid body paragangliomas. <i>Annals of Nuclear Medicine</i> , 2018, 32, 297-301.	2.2	9
27	Liver metastases from medullary thyroid carcinoma detected on 68Ga-FAPI-04 PET/CT. <i>Endocrine</i> , 2021, 74, 727-728.	2.3	8
28	68Ga-PSMA Uptake Patterns of Clear Cell Renal Carcinoma Across Different Histopathological Subtypes. <i>Clinical Nuclear Medicine</i> , 2022, 47, e45-e46.	1.3	8
29	An Incidental Solitary Plasmacytoma of Bone Mimicking Neuroendocrine Tumor Metastasis on 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography. <i>Molecular Imaging and Radionuclide Therapy</i> , 2016, 25, 147-149.	0.7	8
30	Outcome of 177Lu-PSMA Radionuclide Treatment in Advanced Prostate Cancer and Its Association With Clinical Parameters. <i>Clinical Nuclear Medicine</i> , 2022, 47, e521-e528.	1.3	7
31	Impact of Nonosseous Findings on 18F-NaF PET/CT in a Patient with Ductal Breast Carcinoma. <i>Nuclear Medicine and Molecular Imaging</i> , 2014, 48, 72-74.	1.0	6
32	Do 18F-FDG PET/CT findings have a relationship with histopathological and immunohistochemical factors of breast cancer in men?. <i>Nuclear Medicine Communications</i> , 2016, 37, 1273-1281.	1.1	6
33	Clinical Impact of Lower-Limb Imaging in <sup>68</sup> Ga-PSMA PET/CT for Patients with Prostate Cancer. <i>Journal of Nuclear Medicine Technology</i> , 2019, 47, 233-237.	0.8	6
34	Candida esophagitis mimicking esophageal malignancy on 18FDG PET/CT. <i>Turkish Journal of Gastroenterology</i> , 2015, 26, 63-64.	1.1	6
35	Clinical Utility of Tc-99m MIBI SPECT/CT for Preoperative Localization of Parathyroid Lesions. <i>Indian Journal of Surgery</i> , 2017, 79, 312-318.	0.3	5
36	Microscopic polyangiitis on 18F-FDG PET/CT of a patient with fever of unknown origin presenting as isolated diffuse renal hypermetabolism. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1295-1296.	6.4	4

#	ARTICLE	IF	CITATIONS
37	177Lu-PSMA Therapy for Metastatic Testicular Mixed Germ Cell Tumor. <i>Clinical Nuclear Medicine</i> , 2021, 46, 415-418.	1.3	3
38	Demonstration of in vivo estrogen receptor status with $^{16}\alpha$ - [18F]fluoro-17 $\alpha$ -oestradiol (FES) PET/CT in a rare case of benign metastasizing leiomyoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4101-4102.	6.4	3
39	Does Metastatic Lymph Node SUVmax Predict Survival in Patients with Esophageal Cancer?. <i>Molecular Imaging and Radionuclide Therapy</i> , 2015, 24, 120-127.	0.7	3
40	Somatostatin receptor-positive breast lesions on 68Ga-DOTATATE PET/CT. <i>Annals of Nuclear Medicine</i> , 2021, 35, 270-277.	2.2	2
41	Intratumoral Heterogeneity in a Patient With Metastatic Thymic Carcinoma on 18F-FDG, 68Ga-DOTATATE, and 68Ga-FAPI04 PET/CT. <i>Clinical Nuclear Medicine</i> , 2022, 47, e79-e80.	1.3	2
42	Role of red blood cell scintigraphy for determining the localization of gastrointestinal bleeding. <i>Ulusal Travma Ve Acil Cerrahi Dergisi</i> , 2012, 18, 225-230.	0.3	2
43	Comparison of 2D planar and 3D volumetric methods for estimation of split renal function by $^{99m}\text{Tc}$ -DMSA scintigraphy. <i>Physica Medica</i> , 2022, 95, 83-88.	0.7	2
44	Y $\alpha$ ceKSEK R $\alpha$ °SKL $\alpha$ ° PROSTAT KANSER $\alpha$ °NDE 68GA-PSMA PET/BT $\alpha$ °N TEDAV $\alpha$ ° Y $\alpha$ -NET $\alpha$ °M $\alpha$ °NE ETK $\alpha$ °S $\alpha$ °. <i>°stanbul T<math>\alpha</math>±p Fak<math>\alpha</math></i> Dergisi, 2021, 84, .	0.1	1
45	CXCR4 Expression Demonstrated by 68Ga-Pentixafor PET/CT Imaging in a Case of Systemic Mastocytosis Mimicking Lymphoma. <i>Clinical Nuclear Medicine</i> , 2021, Publish Ahead of Print, e563-e564.	1.3	1
46	[68Ga]-Pentixafor PET/CT imaging of lymphoproliferative malignancies. <i>Clinical and Translational Imaging</i> , 0, , 1.	2.1	1
47	Prognostic value of FDG PET-CT in suspected recurrence of colorectal carcinoma: survival outcomes of a 10-year follow-up. <i>Annals of Nuclear Medicine</i> , 2021, , 1.	2.2	1
48	POST-THERAPY IMAGING AFTER RADIOACTIVE IODINE THERAPY FOR DIFFERENTIATED THYROID CANCER: THE CONTRIBUTION OF SPECT-CT IMAGING TO PLANAR IMAGING. <i>European Oral Research</i> , 2019, 81, 106-114.	0.9	0
49	MALIGN PLEVRAL MEZOTELYOMA AYIRICI TANISI VE PROGNOZUNDA 18F-FDG PET/BT $\alpha$ °N ROL $\alpha$ °. <i>°stanbul T<math>\alpha</math>±p Fak<math>\alpha</math></i> Dergisi, 2019, 82, .	0.1	0